Oppenheimer Sees Apnimed's Ph2 Results Worth Watching for ResMed (RMD)

October 14, 2021 9:30 AM EDT
Get Alerts RMD Hot Sheet
Price: $225.54 --0%

Rating Summary:
    11 Buy, 11 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 4 | Down: 11 | New: 14
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Oppenheimer analyst Suraj Kalia reiterated an Outperform rating and $312.00 price target on ResMed (NYSE: RMD) after the Apnimed announced Phase 2 results from the APC-003 and APC-004 studies. Both studies showed statistically significant results with the use of AD109 when compared to placebo for hypoxic burden and AHI.

The analyst stated "If results can continue to be replicated even in certain phenotypes of OSA or AHI categories, the appeal of a potential once-daily oral therapy as a first-line therapy in OSA remains an interesting story to watch."

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $252.25 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments